CA3042186C - Nkx3.2 fragment and pharmaceutical composition comprising same as active ingredient - Google Patents
Nkx3.2 fragment and pharmaceutical composition comprising same as active ingredient Download PDFInfo
- Publication number
- CA3042186C CA3042186C CA3042186A CA3042186A CA3042186C CA 3042186 C CA3042186 C CA 3042186C CA 3042186 A CA3042186 A CA 3042186A CA 3042186 A CA3042186 A CA 3042186A CA 3042186 C CA3042186 C CA 3042186C
- Authority
- CA
- Canada
- Prior art keywords
- seq
- amino acid
- polypeptide
- acid sequence
- arthritis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20160149090 | 2016-11-09 | ||
| KR10-2016-0149090 | 2016-11-09 | ||
| PCT/KR2017/012651 WO2018088813A2 (ko) | 2016-11-09 | 2017-11-09 | Nkx3.2 단편 및 이를 유효성분으로 포함하는 약학 조성물 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3042186A1 CA3042186A1 (en) | 2018-05-17 |
| CA3042186C true CA3042186C (en) | 2021-06-15 |
Family
ID=62110655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3042186A Active CA3042186C (en) | 2016-11-09 | 2017-11-09 | Nkx3.2 fragment and pharmaceutical composition comprising same as active ingredient |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11235025B2 (enExample) |
| EP (2) | EP3835311B1 (enExample) |
| JP (2) | JP6991593B2 (enExample) |
| KR (4) | KR102049978B1 (enExample) |
| CN (2) | CN115925865A (enExample) |
| AU (2) | AU2017358282C1 (enExample) |
| CA (1) | CA3042186C (enExample) |
| ES (2) | ES3009014T3 (enExample) |
| WO (1) | WO2018088813A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3060947B1 (fr) * | 2016-12-28 | 2025-12-26 | Ynsect | Procede de traitement d'insectes comprenant la separation des cuticules de la partie molle des insectes puis la separation de la partie molle en trois fractions |
| CA3112915A1 (en) | 2018-10-19 | 2020-04-23 | Icm Co., Ltd. | Pharmaceutical composition for treating retinal diseases, comprising nkx3.2 and fragment thereof as active ingredients |
| KR102336515B1 (ko) * | 2018-10-25 | 2021-12-07 | 애니젠 주식회사 | 부포린 유도체 및 이의 용도 |
| CN112409454B (zh) * | 2020-11-04 | 2022-07-05 | 青岛农业大学 | 一种法氏囊七肽及其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| JP5996429B2 (ja) * | 2009-09-03 | 2016-09-21 | ジェネンテック， インコーポレイテッド | 関節リウマチの治療、診断及びモニターするための方法 |
| KR101150900B1 (ko) * | 2010-01-26 | 2012-05-30 | 연세대학교 산학협력단 | 퇴행성 관절염 치료 조성물 |
| WO2011093647A2 (en) * | 2010-01-26 | 2011-08-04 | Industry-Academic Cooperation Foundation, Yonsei University | Genes implicated in osteoarthritis and use thereof |
| KR101150990B1 (ko) | 2010-06-19 | 2012-06-13 | 김유정 | 슬롯리스 고정자를 갖는 브러시리스 직류 모터 |
| WO2012097057A2 (en) * | 2011-01-11 | 2012-07-19 | Tufts University | Methods, compositions and kits for modulating trans-differentiation of muscle satellite cells |
| UY35368A (es) * | 2013-03-08 | 2014-10-31 | Irm Llc | Péptidos y composiciones para el tratamiento de daño articular |
| AU2014310360B2 (en) * | 2013-06-11 | 2019-10-24 | PPL (BVI) Limited | Structure, manufacturing and uses of human-derived cell-permeable peptides conjugated with specific biologically active cargo peptides |
| KR102044530B1 (ko) * | 2017-04-21 | 2019-11-14 | 아이씨엠 주식회사 | Nkx3.2 및 이의 단편을 유효성분으로 포함하는 망막질환 치료용 약학적 조성물 |
-
2017
- 2017-11-09 AU AU2017358282A patent/AU2017358282C1/en active Active
- 2017-11-09 ES ES17868981T patent/ES3009014T3/es active Active
- 2017-11-09 JP JP2019545223A patent/JP6991593B2/ja active Active
- 2017-11-09 EP EP21154441.6A patent/EP3835311B1/en active Active
- 2017-11-09 ES ES21154441T patent/ES2987020T3/es active Active
- 2017-11-09 CN CN202211029784.1A patent/CN115925865A/zh active Pending
- 2017-11-09 CN CN201780069569.5A patent/CN110036023B/zh active Active
- 2017-11-09 EP EP17868981.6A patent/EP3539978B1/en active Active
- 2017-11-09 US US16/348,540 patent/US11235025B2/en active Active
- 2017-11-09 WO PCT/KR2017/012651 patent/WO2018088813A2/ko not_active Ceased
- 2017-11-09 CA CA3042186A patent/CA3042186C/en active Active
- 2017-11-09 KR KR1020170148509A patent/KR102049978B1/ko active Active
- 2017-11-09 KR KR1020170148493A patent/KR102049987B1/ko active Active
-
2019
- 2019-11-05 KR KR1020190140236A patent/KR102340761B1/ko active Active
-
2020
- 2020-02-28 US US16/805,370 patent/US11154590B2/en active Active
- 2020-07-24 AU AU2020207879A patent/AU2020207879B2/en active Active
- 2020-11-02 JP JP2020183392A patent/JP7055455B2/ja active Active
- 2020-11-02 KR KR1020200144613A patent/KR102342171B1/ko active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11154590B2 (en) | Nkx3.2 fragment and pharmaceutical composition comprising same as active ingredient | |
| US12414966B2 (en) | Method of treating diabetes with FGF21 and GLP1 double gene-modified cell | |
| JP2021502058A (ja) | Ｒｎａを編集するための組成物および方法 | |
| US11534500B2 (en) | Modified UBE3A gene for a gene therapy approach for angelman syndrome | |
| Tseng et al. | SARS-CoV envelope protein palmitoylation or nucleocapid association is not required for promoting virus-like particle production | |
| WO2008085564A2 (en) | Compositions and methods involving truncated recombinant seven g-protein coupled receptors | |
| US20230192794A1 (en) | Engineered interleukin-22 polypeptides and uses thereof | |
| US20110224133A1 (en) | Highly Potent Peptides To Control Cancer And Neurodegenerative Diseases | |
| JP2005504010A (ja) | 成長ホルモンおよびｆｏｘｍ１ｂを用いた肝臓疾患および肝臓損傷の処置方法 | |
| US20130316958A1 (en) | Highly potent peptides to control cancer and neurodegenerative diseases | |
| US11560412B2 (en) | Compositions comprising GRIM-19 therapeutics and methods of use | |
| EP3884055B1 (en) | Double and inducible suicide gene construct and its use in gene therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20190429 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241030 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241030 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241030 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251023 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251023 |